GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » Tax Provision

ME Therapeutics Holding (XCNQ:METX) Tax Provision : C$0.00 Mil (TTM As of Feb. 2024)


View and export this data going back to 2023. Start your Free Trial

What is ME Therapeutics Holding Tax Provision?

ME Therapeutics Holding's tax provision for the three months ended in Feb. 2024 was C$0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Feb. 2024 was C$0.00 Mil.


ME Therapeutics Holding Tax Provision Historical Data

The historical data trend for ME Therapeutics Holding's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ME Therapeutics Holding Tax Provision Chart

ME Therapeutics Holding Annual Data
Trend Aug22 Aug23
Tax Provision
- -

ME Therapeutics Holding Quarterly Data
Aug22 Dec22 May23 Aug23 Nov23 Feb24
Tax Provision Get a 7-Day Free Trial - - - - -

ME Therapeutics Holding Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ME Therapeutics Holding (XCNQ:METX) Business Description

Comparable Companies
Traded in Other Exchanges
Address
177 Robson Street, Vancouver, BC, CAN, V6B 0N3
ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.

ME Therapeutics Holding (XCNQ:METX) Headlines

No Headlines